Search PubMed⌕ Search

Biomedical subjects

B Wik

Publications and source records attributed to B Wik.

9 recordsLinked to original sources
PubMed1989

[Streptokinase treatment in acute myocardial infarction].

Myocardial necrosis develops gradually after coronary artery occlusion, and in man is completed after several hours. Most infarctions are precipitated by thrombi, and early fibrinolytic treatment should therefore be the rational therapy. Recanalization is achieved in three of four patients whether streptokinase is applied intracoronary or intravenously. Early treatment limits the size of the infarct, and he myocardial function is preserved better in patients treated with streptokinase than in others. Very early treatment, started within one hour from the onset of nitroglycerin-resistant chest pain, may prevent infarction in some patients. Streptokinase reduces mortality after infarction, in total by as much as 25 per cent, and even considerably more when infusion is started early. There is some risk of bleeding, but serious bleeding episodes are rare. Intracoronary application has no advantages as compared with intravenous infusion. Unless there are strong contra-indications, patients with nitroglycerin-resistant chest pain and abnormal ECG should receive streptokinase intravenously in a dose of 1.5 x 10(6) units. Most patients treated with streptokinase should be given acetylsalicylic acid.

Humans↗
PubMed1988

Effect of very early intravenous streptokinase infusion in patients with evolving myocardial infarction.

The effect of very early infusion of 1.5 X 10(6) U of streptokinase intravenously was studied in 29 patients with nitroglycerin-resistant chest pain and ST-segment elevation. Infarct size was estimated from maximal LD1 isoenzyme levels, and the diagnosis confirmed by CK-MB determination. Thrombolytic therapy was started within 1 hour of pain onset in 11 patients (group A), between 1 and 2 hours in 10 (group B), and later than 2 hours in eight patients (group C). Marked differences appeared between the groups. Thus, three patients in group A and one patient in group B did not develop infarction, all had critical LAD stenoses. Three patients in group C died in shock without bleeding. Further, the average maximal LD1 values in the 22 patients who survived their infarction differed significantly between the groups, and were 12.6, 19.1 and 36.2 mu kat/l in groups A, B and C, respectively. In conclusion, very early intravenous streptokinase infusion probably reduces myocardial necrosis, and possible prevents infarction in some patients.

Adult↗
PubMed1982

Phase II study of 4'-epi-doxorubicin in metastatic renal cancer.

In 20 patients with measurable metastatic renal cancer 4'-epi-doxorubicin (Adriamycin) administration (75 mg/m2, every 3 weeks) did not result in any tumor remission. Hematologic and gastrointestinal toxicity was generally mild to moderate. Anthracycline-induced cardiac side effects were not observed in any of the patients.

Adult↗
PubMed1980

Plasma free fatty acids and the incidence of arrhythmias in acute myocardial infarction during treatment with small doses of subcutaneous heparin or warfarin.

In a prospective trial, 99 patients with a history of AMI of less than 12 hours were allocated at random to treatment with subcutaneous heparin, 5 000 IU twice daily, (51 patients) or warfarin (48 patients). In a subsample of 21 patients, 11 in the warfarin group and 10 in the heparin group, fasting FFA analyses were performed before and 2 hours after administration of anticoagulants on days 1 and 2. No measurable increase in FFA concentrations was demonstrated in the heparin-treated patients, in spite of a significant influence on the thrombin clotting time. The frequency of ventricular arrhythmias as detected by continuous tape recordings was equal in the two groups. It is concluded that subcutaneous heparin, 5 000 IU every 12 hours, can be administered to patients with AMI without increasing the risk of arrhythmias as compared with warfarin.

Aged↗